Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
100% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. INSY: No Debt )
INSY' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.81
INSY's Equity to Asset is ranked higher than
83% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. INSY: 0.81 )
INSY' s 10-Year Equity to Asset Range
Min: -3.45   Max: 0.98
Current: 0.81

-3.45
0.98
Interest Coverage 35.09
INSY's Interest Coverage is ranked higher than
88% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: 35.09 )
INSY' s 10-Year Interest Coverage Range
Min: 35.09   Max: 9999.99
Current: 35.09

35.09
9999.99
F-Score: 6
Z-Score: 27.33
M-Score: 107.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 32.63
INSY's Operating margin (%) is ranked higher than
95% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. INSY: 32.63 )
INSY' s 10-Year Operating margin (%) Range
Min: -324863.64   Max: 56.36
Current: 32.63

-324863.64
56.36
Net-margin (%) 31.67
INSY's Net-margin (%) is ranked higher than
96% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. INSY: 31.67 )
INSY' s 10-Year Net-margin (%) Range
Min: -301890.91   Max: 40.67
Current: 31.67

-301890.91
40.67
ROE (%) 43.45
INSY's ROE (%) is ranked higher than
98% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. INSY: 43.45 )
INSY' s 10-Year ROE (%) Range
Min: -176.46   Max: 50.8
Current: 43.45

-176.46
50.8
ROA (%) 35.24
INSY's ROA (%) is ranked higher than
98% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. INSY: 35.24 )
INSY' s 10-Year ROA (%) Range
Min: -1100   Max: 40.15
Current: 35.24

-1100
40.15
ROC (Joel Greenblatt) (%) 148.75
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. INSY: 148.75 )
INSY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3653.16   Max: 6200
Current: 148.75

-3653.16
6200
Revenue Growth (%) 457.20
INSY's Revenue Growth (%) is ranked higher than
100% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. INSY: 457.20 )
INSY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 457.2
Current: 457.2

0
457.2
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

INSY Guru Trades in Q3 2013

Jim Simons 157,700 sh (New)
Steven Cohen 7,997 sh (New)
Chuck Royce 46,080 sh (-81.57%)
» More
Q4 2013

INSY Guru Trades in Q4 2013

Joel Greenblatt 16,108 sh (New)
Chuck Royce Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q1 2014

INSY Guru Trades in Q1 2014

Jim Simons 137,080 sh (New)
Steven Cohen 9,088 sh (New)
Joel Greenblatt 16,982 sh (-29.72%)
» More
Q2 2014

INSY Guru Trades in Q2 2014

Paul Tudor Jones 17,626 sh (New)
Joel Greenblatt 30,111 sh (+77.31%)
Steven Cohen 168,700 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 77.31%0.01%$22.6 - $42.93 $ 34.226%30111
Joel Greenblatt 2014-03-31 Reduce -29.72%$25.807 - $55.58 $ 34.22-13%16982
Joel Greenblatt 2013-12-31 New Buy0.02%$24.01 - $32.72 $ 34.2223%16108
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.90
INSY's P/E(ttm) is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 23.90 )
INSY' s 10-Year P/E(ttm) Range
Min: 17.67   Max: 2102.36
Current: 23.9

17.67
2102.36
P/B 9.72
INSY's P/B is ranked higher than
67% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. INSY: 9.72 )
INSY' s 10-Year P/B Range
Min: 0.03   Max: 17.41
Current: 9.72

0.03
17.41
P/S 7.52
INSY's P/S is ranked higher than
83% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. INSY: 7.52 )
INSY' s 10-Year P/S Range
Min: 1.74   Max: 45119.95
Current: 7.52

1.74
45119.95
PFCF 39.79
INSY's PFCF is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 39.79 )
INSY' s 10-Year PFCF Range
Min: 29.42   Max: 173.14
Current: 39.79

29.42
173.14
EV-to-EBIT 20.70
INSY's EV-to-EBIT is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 20.70 )
INSY' s 10-Year EV-to-EBIT Range
Min: 15.9   Max: 103.5
Current: 20.7

15.9
103.5
Current Ratio 3.61
INSY's Current Ratio is ranked higher than
70% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. INSY: 3.61 )
INSY' s 10-Year Current Ratio Range
Min: 0.14   Max: 318.82
Current: 3.61

0.14
318.82
Quick Ratio 2.74
INSY's Quick Ratio is ranked higher than
68% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. INSY: 2.74 )
INSY' s 10-Year Quick Ratio Range
Min: 0.06   Max: 318.82
Current: 2.74

0.06
318.82

Valuation & Return

vs
industry
vs
history
Price/Net Cash 44.44
INSY's Price/Net Cash is ranked higher than
79% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. INSY: 44.44 )
INSY' s 10-Year Price/Net Cash Range
Min: 0.67   Max: 72.07
Current: 44.44

0.67
72.07
Price/Net Current Asset Value 23.44
INSY's Price/Net Current Asset Value is ranked higher than
79% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. INSY: 23.44 )
INSY' s 10-Year Price/Net Current Asset Value Range
Min: 0.67   Max: 72.07
Current: 23.44

0.67
72.07
Price/Tangible Book 9.73
INSY's Price/Tangible Book is ranked higher than
73% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. INSY: 9.73 )
INSY' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 105.92
Current: 9.73

0.42
105.92
Price/Median PS Value 0.02
INSY's Price/Median PS Value is ranked higher than
100% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. INSY: 0.02 )
INSY' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 113.7
Current: 0.02

0.01
113.7
Price/Graham Number 3.11
INSY's Price/Graham Number is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 3.11 )
INSY' s 10-Year Price/Graham Number Range
Min: 2.12   Max: 5.97
Current: 3.11

2.12
5.97
Earnings Yield (Greenblatt) 4.80
INSY's Earnings Yield (Greenblatt) is ranked higher than
77% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. INSY: 4.80 )
INSY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 6.3
Current: 4.8

1
6.3
Forward Rate of Return (Yacktman) -82.43
INSY's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. INSY: -82.43 )
INSY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -216.7   Max: -75.6
Current: -82.43

-216.7
-75.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPR1.Germany
Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, or BTCP, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting, or CINV, and appetite stimulation in AIDS patients. The Company's proprietary Fentanyl SL Spray and its generic Dronabinol SG Capsule product candidates are both under review for marketing approval by the U.S. Food and Drug Administration, or FDA.
» More Articles for INSY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Other Events Sep 12 2014
Insys Therapeutics, Inc. Named Arizona Bioscience Company of the Year Sep 03 2014
Insys Therapeutics' Cannabidiol Gets Orphan Drug Status Aug 26 2014
FDA names potential Insys treatment an orphan drug Aug 25 2014
FDA names potential Insys treatment an orphan drug Aug 25 2014
INSYS THERAPEUTICS, INC. Financials Aug 22 2014
Novus Aims to Make Medical Cannabis Affordable Aug 22 2014
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Aug 18 2014
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 14 2014
Stocks Stake Out Thin Gains; Intercept, Insys, Autohome Gain Aug 12 2014
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 12 2014
Stock Futures Hem And Haw; Intercept Pharmaceuticals Soars Aug 12 2014
Q2 2014 Insys Therapeutics Inc Earnings Release - Before Market Open Aug 12 2014
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment Aug 11 2014
GW Pharma, Insys Face Off In Cannabis Drug Space Aug 08 2014
MONDAY DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against INSYS... Jul 11 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against INSYS... Jul 11 2014
INSYS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and... Jul 10 2014
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against INSYS... Jul 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK